Aligos Therapeutics
ALGS
37 hedge funds and large institutions have $19.5M invested in Aligos Therapeutics in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 7 closing their positions.
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
6% more funds holding
Funds holding: 35 → 37 (+2)
11.15% less ownership
Funds ownership: 62.06% → 50.92% (-11%)
28% less capital invested
Capital invested by funds: $27.1M → $19.5M (-$7.57M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$1.21M |
| 2 |
SCM
Sio Capital Management
New York
|
+$929K |
| 3 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
+$547K |
| 4 |
LPL Financial
San Diego,
California
|
+$180K |
| 5 |
Squarepoint
New York
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Heights Capital Management
San Francisco,
California
|
-$1.99M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.95M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.88M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$909K |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$731K |
ALGS Hedge Fund Activity: Q2 2025 in Review
37 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q2 2025, worth a combined $19.5M — down 28% from $27.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ALGS positions and 7 closed out — a net gain of 2 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Woodline Partners, adding an estimated $1.21M. The largest seller was Heights Capital Management, exiting entirely with an estimated $1.99M sold.
- 37 institutional investors held Aligos Therapeutics (ALGS) as of Q2 2025, up from 35 in Q1 2025.
- Funds reported $19.5M of Aligos Therapeutics stock for Q2 2025, down 28% quarter-over-quarter.
- 9 funds opened new Aligos Therapeutics positions in Q2 2025 and 7 closed out, a net change of +2 holders.
- The largest Aligos Therapeutics buyer in Q2 2025 was Woodline Partners, an estimated $1.21M added.
- The largest Aligos Therapeutics seller in Q2 2025 was Heights Capital Management, an estimated $1.99M sold.
Based on aggregated 13F filings for Q2 2025.